---

Related Topics

---

• Paxlovid is an investigational antiviral drug used to treat COVID-19 in both adults and children.^[1]

• Pfizer’s oral version of paxlovid significantly reduced hospital admissions and deaths in people infected with SARS-CoV-2.

• The study included 1219 adults who were registered by September 29, 2021.

• Participants who received paxlovid within 3 days of the onset of COVID-19 symptoms had an 11 percent chance of getting admitted to a hospital or death related to COVID-19.

• In contrast, participants who received the placebo had an 89 percent chance for the same consequences.

• Paxlovid contains two medications namely nirmatrelvir and ritonavir which are protease inhibitors.^[1]

• Participants treated with paxlovid within 5 days of the onset of symptoms had only 1 percent chance of getting admitted up to day 28 with no deaths while participants in the placebo group had 6.7 percent with 10 deaths.

• Safety analysis revealed that people treated with paxlovid had 1.7 percent chance of experiencing serious adverse events while people treated with placebo had 6.6 percent chance.

Sources:

Mahase E. (2021). Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ (Clinical research ed.), 375, n2713. https://doi.org/10.1136/bmj.n2713

[1] https://www.drugs.com/paxlovid.html

AI Disclosure Statement:
The Chromoscience uses AI-assisted tools to support the preparation and editing of science articles. Content is reviewed by the editor for clarity and consistency with the cited research before publication. Readers are encouraged to consult the original scientific publications for complete findings, methods, and limitations.